Usefulness of the High-sensitivity Lung Cancer Compact Panel™ with Cytological Specimens

DOI Web Site 1 Citations 8 References
  • Minami Daisuke
    Department of Respiratory Medicine, Himeji Saint Mary's Hospital Department of Respiratory Medicine, Hosoya Hospital
  • Takigawa Nagio
    Department of Internal Medicine, Himeji Saint Mary's Hospital Department of Internal Medicine 4, Kawasaki Medical School
  • Tada Akio
    Department of Respiratory Medicine, Himeji Saint Mary's Hospital
  • Nakajima Yasuhiro
    Department of Respiratory Medicine, Himeji Saint Mary's Hospital
  • Miyahara Nobuaki
    Department of Internal Medicine, Himeji Saint Mary's Hospital
  • Mizumori Yasuyuki
    Department of Respiratory Medicine, National Hospital Organization Himeji Medical Center
  • Ueda Mitsuhiro
    Department of Thoracic Surgery, National Hospital Organization Himeji Medical Center
  • Sato Yoshiharu
    DNA Chip Research Inc.
  • Morikawa Kei
    Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine
  • Kanehiro Arihiko
    Department of Internal Medicine, Himeji Saint Mary's Hospital

Bibliographic Information

Other Title
  • 細胞診検体を用いた肺がんコンパクトパネルによる次世代シーケンシングの有用性

Search this article

Abstract

<p>Objective. We verified the usefulness of a new next-generation sequencing modality with the Lung Cancer Compact Panel™ using cytological specimens. Study Design. From December 2021 to February 2022, the wash fluid of lung tumors from 10 patients obtained using endobronchial ultrasonography (EBUS) with a guide sheath (GS), EBUS transbronchial needle aspiration (EBUS-TBNA), and pleural effusion puncture was examined with the Lung Cancer Compact Panel™. We examined the patients' medical records to obtain information on the analysis success rate and detection rate of gene mutations in consecutive cases searched for driver gene mutations. Results. Ten patients (6 lung adenocarcinoma, and 1 each of lung squamous cell carcinoma, small-cell lung cancer, renal cell carcinoma, and organizing pneumonia) and 12 samples (7 from brushing, 2 from EBUS-TBNA, 1 from a transbronchial biopsy [TBB] plus brushing, 1 from a TBB, and 1 from brushing) were examined using the Lung Cancer Compact Panel™. We successfully analyzed all tests in all 10 patients (100%). EGFR L858R, KRAS G12D, or KRAS G12V was detected in lung adenocarcinoma patients. KRAS G12V was detected in the lung squamous cell carcinoma patient. The amounts of nucleic acids from the pleural effusion puncture and EBUS-TBNA were sufficient for the analyses. Conclusion. The Lung Cancer Compact Panel™ was useful for detecting gene mutations using cytological specimens.</p>

Journal

  • Haigan

    Haigan 62 (7), 989-995, 2022-12-20

    The Japan Lung Cancer Society

Citations (1)*help

See more

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top